Literature DB >> 31994704

Impact of Difficult-to-Treat Resistance in Gram-negative Bacteremia on Mortality: Retrospective Analysis of Nationwide Surveillance Data.

Kyungmin Huh1,2, Doo Ryeon Chung1,2, Young Eun Ha3, Jae-Hoon Ko1, Si-Ho Kim1, Min-Ji Kim4, Hee Jae Huh5, Nam Yong Lee5, Sun Young Cho1, Cheol-In Kang1, Kyong Ran Peck1, Jae-Hoon Song1,2.   

Abstract

BACKGROUND: Clinically relevant categorization of antimicrobial resistance is critical to mitigating the threat it poses. Difficult-to-treat resistance (DTR) is a recently proposed category defined as nonsusceptibility to all first-line antibiotic agents.
METHODS: A retrospective study was conducted with nonduplicate cases of gram-negative bloodstream infection (GNBSI) caused by 4 major taxa (Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter species) identified from a nationwide surveillance database. DTR was defined as nonsusceptibility to all the β-lactams and fluoroquinolones tested. Patient characteristics and mortality were compared between DTR GNBSI and GNBSI caused by carbapenem-resistant but not DTR and extended-spectrum cephalosporin-resistant but not DTR isolates using Centers for Disease Control and Prevention definitions. Adjusted odds ratios (aORs) for 30-day in-hospital mortality were examined for DTR in overall and in propensity score-matched cohorts.
RESULTS: A total of 1167 episodes of monomicrobial GNBSI were identified, and 147 (12.6%) of the isolates were DTR. The majority of DTR isolates were Acinetobacter species (79.6%) and P. aeruginosa (17.7%). DTR infections were associated with previous antibiotic use, healthcare contact, ventilator use, and lower respiratory tract infection. Crude mortality for GNBSI caused by DTR was 50.3%. A multivariable model showed that only DTR, but not other categories, was significantly associated with mortality (adjusted odds ratio [aOR], 3.58 [95% confidence interval {CI}, 1.27-10.19]). DTR was also a significant predictor for mortality in the analysis of propensity score-matched cohorts (aOR, 3.48 [95% CI, 1.82-6.79]).
CONCLUSIONS: In patients with GNBSI, DTR was associated with higher mortality than those in other resistance categories. Our findings suggest that DTR could be useful for surveillance and prognostication.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  antibiotic resistance; bacteremia; gram-negative bacteria; mortality; treatment outcome

Year:  2020        PMID: 31994704     DOI: 10.1093/cid/ciaa084

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

Review 1.  Facilitating Compound Entry as a Means to Discover Antibiotics for Gram-Negative Bacteria.

Authors:  Kristen A Muñoz; Paul J Hergenrother
Journal:  Acc Chem Res       Date:  2021-02-26       Impact factor: 22.384

2.  Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000-2017.

Authors:  Ahmed Babiker; Lloyd G Clarke; Melissa Saul; Julie A Gealey; Cornelius J Clancy; M Hong Nguyen; Ryan K Shields
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

3.  Clinical Outcomes, Microbiological Characteristics and Risk Factors for Difficult-to-Treat Resistance to Klebsiella pneumoniae Infection.

Authors:  Liyan Cui; Ning Shen; Ping Yang; Chao Liu; Zhenchao Wu; Jiajia Zheng; Juan Yi; Nan Wu; Zhangli Wu; Ming Lu
Journal:  Infect Drug Resist       Date:  2022-10-17       Impact factor: 4.177

4.  In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020.

Authors:  James A Karlowsky; Sibylle H Lob; C Andrew DeRyke; David W Hilbert; Michael T Wong; Katherine Young; Fakhar Siddiqui; Mary R Motyl; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2022-05-02       Impact factor: 5.938

5.  Difference in the Clinical Outcome of Bloodstream Infections Caused by Klebsiella aerogenes and Enterobacter cloacae Complex.

Authors:  Minji Jeon; Kyungmin Huh; Jae-Hoon Ko; Sun Young Cho; Hee Jae Huh; Nam Yong Lee; Cheol-In Kang; Doo Ryeon Chung; Kyong Ran Peck
Journal:  Open Forum Infect Dis       Date:  2021-07-20       Impact factor: 3.835

6.  Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.

Authors:  Eric Wenzler; David Butler; Xing Tan; Takayuki Katsube; Toshihiro Wajima
Journal:  Clin Pharmacokinet       Date:  2021-11-18       Impact factor: 5.577

7.  Key Takeaways From the U.S. CDC's 2019 Antibiotic Resistance Threats Report for Frontline Providers.

Authors:  Sameer S Kadri
Journal:  Crit Care Med       Date:  2020-07       Impact factor: 7.598

8.  Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study.

Authors:  Jeffrey R Strich; Sarah Warner; Yi Ling Lai; Cumhur Y Demirkale; John H Powers; Robert L Danner; Sameer S Kadri
Journal:  Lancet Infect Dis       Date:  2020-06-04       Impact factor: 71.421

9.  Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant Pseudomonas aeruginosa Meningitis.

Authors:  Erin K McCreary; Karin E Byers; Carolyn Fernandes; Ellen G Kline; David P Nicolau; Ryan K Shields
Journal:  Open Forum Infect Dis       Date:  2020-11-12       Impact factor: 4.423

10.  In vitro activity of ceftazidime/avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from Middle Eastern and African countries: ATLAS global surveillance programme 2015-18.

Authors:  James A Karlowsky; Samuel K Bouchillon; Ramy El Mahdy Kotb; Naglaa Mohamed; Gregory G Stone; Daniel F Sahm
Journal:  JAC Antimicrob Resist       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.